Premium
Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor
Author(s) -
Carmen Collado M,
Beleta Jorge,
Martinez Ester,
Miralpeix Montse,
Domènech Teresa,
Maria Palacios José,
Hernández Jesús
Publication year - 1998
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0701698
Subject(s) - diazepam , chemistry , inverse agonist , rolipram , flumazenil , gabaa receptor , pharmacology , phosphodiesterase , milrinone , benzodiazepine , antagonist , endocrinology , medicine , receptor , biochemistry , biology , enzyme , inotrope
1 The responses of the electrically‐driven right ventricle strip of the guinea‐pig heart to diazepam were recorded in the absence and in the presence of different selective cyclic nucleotide phosphodiesterase (PDE) inhibitors. 2 Diazepam, at concentrations ranging from 1 μ M to 100 μ M , was devoid of effect on the contractile force in this preparation. 3 Conversely, diazepam (5 μ M –100 μ M ) produced a consistent positive inotropic response in the presence of a concentration (1 μ M ), that was without effect in the absence of diazepam, of either of the selective PDE 3 inhibitors milrinone or SK&F 94120, but not in the presence of the selective PDE 4 inhibitor rolipram. 4 This effect of diazepam was not γ‐aminobutyric acid (GABA)‐dependent, since it was neither mimicked nor potentiated by GABA, and was not affected by either a high concentration (5 μ M ) of the antagonists of the benzodiazepine/GABA/channel chloride receptor complex, picrotoxin, flumazenil and β‐carboline‐3‐carboxylic acid methyl ester (βCCMe), or by the inverse agonists, β‐carboline‐3‐carboxylic acid N‐methylamide (βCCMa) and methyl 6,7‐dimethoxy‐4‐ethyl‐β‐carboline‐3‐carboxylate (DMCM, 0.1 μ M ). Furthermore, a specific antagonist of the peripheral benzodiazepine receptors, PK 11195 (5 μ M ), did not influence the effect of diazepam. 5 Biochemical studies with isolated PDEs, confirmed that diazepam selectively inhibits type 4 PDE from guinea‐pig right ventricle rather than the other PDEs present in that tissue. The compound inhibited this enzyme in a non‐competitive manner. Diazepam was also able to inhibit PDE 5, the cyclic GMP specific PDE absent from cardiac muscle, with a potency close to that shown for PDE 4. 6 Diazepam displaced the selective type 4 PDE inhibitor, rolipram from its high affinity binding site in rat brain cortex membranes, and also potentiated the rise in cyclic AMP levels induced by isoprenaline in guinea‐pig eosinophils, where only type 4 PDE is present. 7 The PDE inhibitory properties of diazepam were shared, although with lower potency, by other structurally‐related benzodiazepines, that also displaced [ 3 H]‐rolipram from its high affinity binding site. The order of potency found for these compounds in these assays was not related to their potencies as modulators of the GABA receptor through its benzodiazepine binding site. 8 The pharmacological and biochemical data presented in this study indicate that diazepam behaves as a selective type 4 PDE inhibitor in cardiac tissue and this effect seems neither to be mediated by the benzodiazepine/GABA/channel chloride receptor complex nor by peripheral type benzodiazepine receptors.British Journal of Pharmacology (1998) 123 , 1047–1054; doi: 10.1038/sj.bjp.0701698